Statistics on mortality following acute myocardial infarction in 842 897 EuropeansCitation formats

  • External authors:
  • Tomas Jernberg
  • Mar Pujades-Rodriguez
  • Mark J. Rutherford
  • Robert M. West
  • Marlous Hall
  • Adam Timmis
  • Bertil Lindahl
  • Keith A. A. Fox
  • Harry Hemingway
  • Chris P. Gale

Standard

Statistics on mortality following acute myocardial infarction in 842 897 Europeans. / Alabas, Oras A.; Jernberg, Tomas; Pujades-Rodriguez, Mar; Rutherford, Mark J.; West, Robert M.; Hall, Marlous; Timmis, Adam; Lindahl, Bertil; Fox, Keith A. A.; Hemingway, Harry; Gale, Chris P.

In: Cardiovascular research, Vol. 116, No. 1, 26.07.2020, p. 149-157.

Research output: Contribution to journalArticlepeer-review

Harvard

Alabas, OA, Jernberg, T, Pujades-Rodriguez, M, Rutherford, MJ, West, RM, Hall, M, Timmis, A, Lindahl, B, Fox, KAA, Hemingway, H & Gale, CP 2020, 'Statistics on mortality following acute myocardial infarction in 842 897 Europeans', Cardiovascular research, vol. 116, no. 1, pp. 149-157. https://doi.org/10.1093/cvr/cvz197

APA

Alabas, O. A., Jernberg, T., Pujades-Rodriguez, M., Rutherford, M. J., West, R. M., Hall, M., Timmis, A., Lindahl, B., Fox, K. A. A., Hemingway, H., & Gale, C. P. (2020). Statistics on mortality following acute myocardial infarction in 842 897 Europeans. Cardiovascular research, 116(1), 149-157. https://doi.org/10.1093/cvr/cvz197

Vancouver

Alabas OA, Jernberg T, Pujades-Rodriguez M, Rutherford MJ, West RM, Hall M et al. Statistics on mortality following acute myocardial infarction in 842 897 Europeans. Cardiovascular research. 2020 Jul 26;116(1):149-157. https://doi.org/10.1093/cvr/cvz197

Author

Alabas, Oras A. ; Jernberg, Tomas ; Pujades-Rodriguez, Mar ; Rutherford, Mark J. ; West, Robert M. ; Hall, Marlous ; Timmis, Adam ; Lindahl, Bertil ; Fox, Keith A. A. ; Hemingway, Harry ; Gale, Chris P. / Statistics on mortality following acute myocardial infarction in 842 897 Europeans. In: Cardiovascular research. 2020 ; Vol. 116, No. 1. pp. 149-157.

Bibtex

@article{77647347346b4db0bc3ecebc51e98b1e,
title = "Statistics on mortality following acute myocardial infarction in 842 897 Europeans",
abstract = "Aims: To compare ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) mortality between Sweden and the UK, adjusting for background population rates of expected death, case mix, and treatments. Methods and results: National data were collected from hospitals in Sweden [n = 73 hospitals, 180 368 patients, Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)] and the UK [n = 247, 662 529 patients, Myocardial Ischaemia National Audit Project (MINAP)] between 2003 and 2013. There were lower rates of revascularization [STEMI (43.8% vs. 74.9%); NSTEMI (27.5% vs. 43.6%)] and pharmacotherapies at time of hospital discharge including [aspirin (82.9% vs. 90.2%) and (79.9% vs. 88.0%), β-blockers (73.4% vs. 86.4%) and (65.3% vs. 85.1%)] in the UK compared with Sweden, respectively. Standardized net probability of death (NPD) between admission and 1 month was higher in the UK for STEMI [8.0 (95% confidence interval 7.4-8.5) vs. 6.7 (6.5-6.9)] and NSTEMI [6.8 (6.4-7.2) vs. 4.9 (4.7-5.0)]. Between 6 months and 1 year and more than 1 year, NPD remained higher in the UK for NSTEMI [2.9 (2.5-3.3) vs. 2.3 (2.2-2.5)] and [21.4 (20.0-22.8) vs. 18.3 (17.6-19.0)], but was similar for STEMI [0.7 (0.4-1.0) vs. 0.9 (0.7-1.0)] and [8.4 (6.7-10.1) vs. 8.3 (7.5-9.1)]. Conclusion: Short-term mortality following STEMI and NSTEMI was higher in the UK compared with Sweden. Mid-and longer-term mortality remained higher in the UK for NSTEMI but was similar for STEMI. Differences in mortality may be due to differential use of guideline-indicated treatments.",
keywords = "Acute myocardial infarction, MINAP, Mortality, SWEDEHEART, Sweden, UK",
author = "Alabas, {Oras A.} and Tomas Jernberg and Mar Pujades-Rodriguez and Rutherford, {Mark J.} and West, {Robert M.} and Marlous Hall and Adam Timmis and Bertil Lindahl and Fox, {Keith A. A.} and Harry Hemingway and Gale, {Chris P.}",
note = "Publisher Copyright: {\textcopyright} 2019 Published on behalf of the European Society of Cardiology. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = jul,
day = "26",
doi = "10.1093/cvr/cvz197",
language = "English",
volume = "116",
pages = "149--157",
journal = "Cardiovascular research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Statistics on mortality following acute myocardial infarction in 842 897 Europeans

AU - Alabas, Oras A.

AU - Jernberg, Tomas

AU - Pujades-Rodriguez, Mar

AU - Rutherford, Mark J.

AU - West, Robert M.

AU - Hall, Marlous

AU - Timmis, Adam

AU - Lindahl, Bertil

AU - Fox, Keith A. A.

AU - Hemingway, Harry

AU - Gale, Chris P.

N1 - Publisher Copyright: © 2019 Published on behalf of the European Society of Cardiology. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/7/26

Y1 - 2020/7/26

N2 - Aims: To compare ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) mortality between Sweden and the UK, adjusting for background population rates of expected death, case mix, and treatments. Methods and results: National data were collected from hospitals in Sweden [n = 73 hospitals, 180 368 patients, Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)] and the UK [n = 247, 662 529 patients, Myocardial Ischaemia National Audit Project (MINAP)] between 2003 and 2013. There were lower rates of revascularization [STEMI (43.8% vs. 74.9%); NSTEMI (27.5% vs. 43.6%)] and pharmacotherapies at time of hospital discharge including [aspirin (82.9% vs. 90.2%) and (79.9% vs. 88.0%), β-blockers (73.4% vs. 86.4%) and (65.3% vs. 85.1%)] in the UK compared with Sweden, respectively. Standardized net probability of death (NPD) between admission and 1 month was higher in the UK for STEMI [8.0 (95% confidence interval 7.4-8.5) vs. 6.7 (6.5-6.9)] and NSTEMI [6.8 (6.4-7.2) vs. 4.9 (4.7-5.0)]. Between 6 months and 1 year and more than 1 year, NPD remained higher in the UK for NSTEMI [2.9 (2.5-3.3) vs. 2.3 (2.2-2.5)] and [21.4 (20.0-22.8) vs. 18.3 (17.6-19.0)], but was similar for STEMI [0.7 (0.4-1.0) vs. 0.9 (0.7-1.0)] and [8.4 (6.7-10.1) vs. 8.3 (7.5-9.1)]. Conclusion: Short-term mortality following STEMI and NSTEMI was higher in the UK compared with Sweden. Mid-and longer-term mortality remained higher in the UK for NSTEMI but was similar for STEMI. Differences in mortality may be due to differential use of guideline-indicated treatments.

AB - Aims: To compare ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) mortality between Sweden and the UK, adjusting for background population rates of expected death, case mix, and treatments. Methods and results: National data were collected from hospitals in Sweden [n = 73 hospitals, 180 368 patients, Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)] and the UK [n = 247, 662 529 patients, Myocardial Ischaemia National Audit Project (MINAP)] between 2003 and 2013. There were lower rates of revascularization [STEMI (43.8% vs. 74.9%); NSTEMI (27.5% vs. 43.6%)] and pharmacotherapies at time of hospital discharge including [aspirin (82.9% vs. 90.2%) and (79.9% vs. 88.0%), β-blockers (73.4% vs. 86.4%) and (65.3% vs. 85.1%)] in the UK compared with Sweden, respectively. Standardized net probability of death (NPD) between admission and 1 month was higher in the UK for STEMI [8.0 (95% confidence interval 7.4-8.5) vs. 6.7 (6.5-6.9)] and NSTEMI [6.8 (6.4-7.2) vs. 4.9 (4.7-5.0)]. Between 6 months and 1 year and more than 1 year, NPD remained higher in the UK for NSTEMI [2.9 (2.5-3.3) vs. 2.3 (2.2-2.5)] and [21.4 (20.0-22.8) vs. 18.3 (17.6-19.0)], but was similar for STEMI [0.7 (0.4-1.0) vs. 0.9 (0.7-1.0)] and [8.4 (6.7-10.1) vs. 8.3 (7.5-9.1)]. Conclusion: Short-term mortality following STEMI and NSTEMI was higher in the UK compared with Sweden. Mid-and longer-term mortality remained higher in the UK for NSTEMI but was similar for STEMI. Differences in mortality may be due to differential use of guideline-indicated treatments.

KW - Acute myocardial infarction

KW - MINAP

KW - Mortality

KW - SWEDEHEART

KW - Sweden

KW - UK

U2 - 10.1093/cvr/cvz197

DO - 10.1093/cvr/cvz197

M3 - Article

VL - 116

SP - 149

EP - 157

JO - Cardiovascular research

JF - Cardiovascular research

SN - 0008-6363

IS - 1

ER -